Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Steven Cohen’s SAC Capital Increased Its Position in $ITMN

Steven Cohen’s SAC Capital declared on October 14th that the firm has increased its passive stock position in Intermune Inc. (ITMN) to 3.37 million shares, giving a 5.2% stake of the company. SAC Capital reported only 595 thousand shares in ITMN in the second quarter, so now its position is more than quintuple. ITMN experienced a large slump in early August, and dropped by more than 40%. The stock has lost 35% year to date and is wavering throughout the third quarter. Steven Cohen might enter at about $21 in late September. The buy-side volume led to a 3-day’s rise since Steven Cohen passed the 5% threshold on October 3rd. The stock is now trading at 23.68%, up by 3% after Steven Cohen’s 13G filing.


Twenty hedge funds in Insider Monkey’s tracking list had ITMN in their portfolios in the second quarter. David Elliot Shaw’s D E Shaw increased its position by 177% and had 4.15 million shares, corresponding to a 6.4% stake. Anand Parekh’s Alyeska Investment Group increased its position by 55% to 3.10 million shares, giving a 4.78% stake. Daniel Gold’s Qvt Financial cut its position by 19% and retained 2.76 million shares, or 4.26% stake.

Stamford, Connecticut-based SAC Capital is founded by Steven Cohen in 1992. SAC is a diversified hedge fund that uses both fundamental and quantitative analysis based approaches. Cohen is one of the legendary traders and a billionaire. He is estimated to have an $8 Billion new worth.

Intermune Inc. is a biopharmaceutical company. It engages in developing and commercializing therapies in pulmonology and hepatology. The company primarily operates two product portfolios, including pulmonology product portfolio and hepatology product portfolio. The company was founded in 1998 and is based in Brisbane, California.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!